Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT05896761




Registration number
NCT05896761
Ethics application status
Date submitted
31/05/2023
Date registered
9/06/2023
Date last updated
18/09/2023

Titles & IDs
Public title
A Sub-study of Cabotegravir (CAB) and Rilpivirine (RPV) in Human Immunodeficiency Viruses (HIV)-Infected Participants
Scientific title
Sub-study to the A2M Study to Evaluate the Pharmacokinetics, Tolerability and Efficacy of Cabotegravir and Rilpivirine Long-Acting Injections Following Intramuscular Administration in the Vastus Lateralis Muscle (Thigh) in HIV-infected Adult Participants Who Have Received at Least Three Years of Gluteal Injections in the A2M Study
Secondary ID [1] 0 0
207966-001
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Human Immunodeficiency Virus Type 1 (HIV-1) 0 0
Condition category
Condition code
Infection 0 0 0 0
Acquired immune deficiency syndrome (AIDS / HIV)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Cabotegravir Injectable Suspension
Treatment: Drugs - Rilpivirine Injectable Suspension

Experimental: Participants receiving CAB LA 400 milligrams (mg) and RPV LA 600 mg - Participants will receive an Intramuscular (IM) injection of CAB LA 400 mg on one lateral thigh and RPV LA 600 mg into the opposite lateral thigh on Day 1 in every 4 weeks (Q4W) for a total of 16 weeks during Thigh injection phase. Participants will then return to the clinic 4 weeks later to receive their first IM gluteal injection (at Week 16) of CAB LA 400 mg and RPV LA 600 mg during the Return to Gluteal Injection Phase. The subsequent gluteal injection will occur at Week 20.

Experimental: Participants receiving CAB LA 600 mg and RPV LA 900 mg - Participants will receive an IM injection of CAB LA 600 mg on one lateral thigh and RPV LA 900 mg into the opposite lateral thigh on Day 1 in every 8 weeks (Q8W) for a total of 16 weeks during Thigh injection phase. Participants will then return to the clinic 8 weeks later receive their first IM gluteal injection (at Week 16) of CAB LA 600mg and RPV LA 900 mg during the Return to Gluteal Injection phase. The subsequent gluteal injection will occur at Week 24.


Treatment: Drugs: Cabotegravir Injectable Suspension
CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 milligrams per milliliter (mg/mL) of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be frozen.

Treatment: Drugs: Rilpivirine Injectable Suspension
RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be frozen. RPV LA should also be protected from light.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Concentration at End of Dosing Interval (Ctau) of CAB LA Following Administration of CAB LA + RPV LA Q8W
Timepoint [1] 0 0
Weeks -8,-7,-4 and Pre-dose on Day 1(Pre-Thigh Gluteal Injection);2 Hours post-dose on Day 1,Pre-dose on Week 8,Weeks 1 and 4 post-dose(First Thigh Injection);2 Hours post-dose on Week 8 and Weeks 9, 12 post-dose,Pre-dose on Week 16(Last Thigh Injection)
Primary outcome [2] 0 0
Concentration at End of Dosing Interval (Ctau) of RPV LA Following Administration of CAB LA + RPV LA Q8W
Timepoint [2] 0 0
Weeks -8,-7,-4 and Pre-dose on Day 1(Pre-Thigh Gluteal Injection);2 Hours post-dose on Day 1,Pre-dose on Week 8,Weeks 1 and 4 post-dose(First Thigh Injection);2 Hours post-dose on Week 8 and Weeks 9, 12 post-dose,Pre-dose on Week 16(Last Thigh Injection)
Primary outcome [3] 0 0
Maximum Plasma Concentration (Cmax) of CAB LA Following Administration of CAB LA + RPV LA Q8W
Timepoint [3] 0 0
Weeks -8,-7,-4 and Pre-dose on Day 1(Pre-Thigh Gluteal Injection);2 Hours post-dose on Day 1,Pre-dose on Week 8,Weeks 1 and 4 post-dose(First Thigh Injection);2 Hours post-dose on Week 8 and Weeks 9, 12 post-dose,Pre-dose on Week 16(Last Thigh Injection)
Primary outcome [4] 0 0
Maximum Plasma Concentration (Cmax) of RPV LA Following Administration of CAB LA + RPV LA Q8W
Timepoint [4] 0 0
Weeks -8,-7,-4 and Pre-dose on Day 1(Pre-Thigh Gluteal Injection);2 Hours post-dose on Day 1,Pre-dose on Week 8,Weeks 1 and 4 post-dose(First Thigh Injection);2 Hours post-dose on Week 8 and Weeks 9, 12 post-dose,Pre-dose on Week 16(Last Thigh Injection)
Primary outcome [5] 0 0
Area Under the Concentration Curve From 0 Hours to the Time of Next Dosing (AUC [0-tau]) of CAB LA Following Administration of CAB LA + RPV LA Q8W
Timepoint [5] 0 0
Weeks -8,-7,-4 and Pre-dose on Day 1(Pre-Thigh Gluteal Injection);2 Hours post-dose on Day 1,Pre-dose on Week 8,Weeks 1 and 4 post-dose(First Thigh Injection);2 Hours post-dose on Week 8 and Weeks 9, 12 post-dose,Pre-dose on Week 16(Last Thigh Injection)
Primary outcome [6] 0 0
Area Under the Concentration Curve From 0 Hours to the Time of Next Dosing (AUC [0-tau]) of RPV LA Following Administration of CAB LA + RPV LA Q8W
Timepoint [6] 0 0
Weeks -8,-7,-4 and Pre-dose on Day 1(Pre-Thigh Gluteal Injection);2 Hours post-dose on Day 1,Pre-dose on Week 8,Weeks 1 and 4 post-dose(First Thigh Injection);2 Hours post-dose on Week 8 and Weeks 9, 12 post-dose,Pre-dose on Week 16(Last Thigh Injection)
Primary outcome [7] 0 0
Concentration at End of Dosing Interval (Ctau) of CAB LA Following Administration of CAB LA + RPV LA Q4W
Timepoint [7] 0 0
Weeks -4 and -3, Pre-dose on Day 1 (Pre-Thigh Gluteal Injection); 2 Hours post-dose on Day 1, Week 1 post-dose, Pre-dose on Week 4 (First Thigh Injection); 2 Hours post-dose on Week 12, Week 13 post-dose and Pre-dose on Week 16 (Last Thigh Injection)
Primary outcome [8] 0 0
Concentration at End of Dosing Interval (Ctau) of RPV LA Following Administration of CAB LA + RPV LA Q4W
Timepoint [8] 0 0
Weeks -4 and -3, Pre-dose on Day 1 (Pre-Thigh Gluteal Injection); 2 Hours post-dose on Day 1, Week 1 post-dose, Pre-dose on Week 4 (First Thigh Injection); 2 Hours post-dose on Week 12, Week 13 post-dose and Pre-dose on Week 16 (Last Thigh Injection)
Primary outcome [9] 0 0
Maximum Plasma Concentration (Cmax) of CAB LA Following Administration of CAB LA + RPV LA Q4W
Timepoint [9] 0 0
Weeks -4 and -3, Pre-dose on Day 1 (Pre-Thigh Gluteal Injection); 2 Hours post-dose on Day 1, Week 1 post-dose, Pre-dose on Week 4 (First Thigh Injection); 2 Hours post-dose on Week 12, Week 13 post-dose and Pre-dose on Week 16 (Last Thigh Injection)
Primary outcome [10] 0 0
Maximum Plasma Concentration (Cmax) of RPV LA Following Administration of CAB LA + RPV LA Q4W
Timepoint [10] 0 0
Weeks -4 and -3, Pre-dose on Day 1 (Pre-Thigh Gluteal Injection); 2 Hours post-dose on Day 1, Week 1 post-dose, Pre-dose on Week 4 (First Thigh Injection); 2 Hours post-dose on Week 12, Week 13 post-dose and Pre-dose on Week 16 (Last Thigh Injection)
Primary outcome [11] 0 0
Area Under the Concentration Curve From 0 Hours to the Time of Next Dosing (AUC [0-tau]) of CAB LA Following Administration of CAB LA + RPV LA Q4W
Timepoint [11] 0 0
Weeks -4 and -3, Pre-dose on Day 1 (Pre-Thigh Gluteal Injection); 2 Hours post-dose on Day 1, Week 1 post-dose, Pre-dose on Week 4 (First Thigh Injection); 2 Hours post-dose on Week 12, Week 13 post-dose and Pre-dose on Week 16 (Last Thigh Injection)
Primary outcome [12] 0 0
Area Under the Concentration Curve From 0 Hours to the Time of Next Dosing (AUC [0-tau]) of RPV LA Following Administration of CAB LA + RPV LA Q4W
Timepoint [12] 0 0
Weeks -4 and -3, Pre-dose on Day 1 (Pre-Thigh Gluteal Injection); 2 Hours post-dose on Day 1, Week 1 post-dose, Pre-dose on Week 4 (First Thigh Injection); 2 Hours post-dose on Week 12, Week 13 post-dose and Pre-dose on Week 16 (Last Thigh Injection)
Secondary outcome [1] 0 0
Number of Participants With Injection Site Reactions (ISRs) by Maximum Severity Grade - Thigh Injection Phase
Timepoint [1] 0 0
Up to Week 16
Secondary outcome [2] 0 0
Number of Participants With Adverse Events of Special Interest (AESI) Based on Maximum Severity Grade- Thigh Injection Phase
Timepoint [2] 0 0
Up to Week 16
Secondary outcome [3] 0 0
Number of Participants Who Discontinue Treatment Due to ISRs and AESIs-Thigh Injection Phase
Timepoint [3] 0 0
Up to Week 16
Secondary outcome [4] 0 0
Percentage of Participants With Plasma HIV-1 Ribonucleic Acid (RNA) Less Than (<)50 Copies Per Milliliter (Copies/mL) Using the Food and Drug (FDA) Snapshot Algorithm-Thigh Injection Phase
Timepoint [4] 0 0
Baseline (Day 1) and at Weeks 4, 8, 12, 16
Secondary outcome [5] 0 0
Percentage of Participants With Plasma HIV RNA Greater Than or Equal to (>=)50 Copies/mL Over Time as Per the FDA Snapshot Algorithm- Thigh Injection Phase
Timepoint [5] 0 0
Baseline (Day 1) and at Weeks 4, 8, 12, 16
Secondary outcome [6] 0 0
Percentage of Participants With Protocol-defined Confirmed Virologic Failure (CVF)- Thigh Injection Phase
Timepoint [6] 0 0
Up to Week 16
Secondary outcome [7] 0 0
Number of Participants With Treatment Emergent Genotypic Resistance - Thigh Injection Phase
Timepoint [7] 0 0
Up to Week 16
Secondary outcome [8] 0 0
Number of Participants With Treatment Emergent Phenotypic Resistance - Thigh Injection Phase
Timepoint [8] 0 0
Up to Week 16
Secondary outcome [9] 0 0
Number of Participants With Post-injection Pain Using Numerical Rating Scale (NRS) on Day 1-Thigh Injection Phase
Timepoint [9] 0 0
Day 1
Secondary outcome [10] 0 0
Number of Participants With Post-injection Pain Using Numerical Rating Scale (NRS) for CAB LA + RPV LA Q8W Arm on Week 8- Thigh Injection Phase
Timepoint [10] 0 0
Week 8
Secondary outcome [11] 0 0
Number of Participants With Post-injection Pain Using Numerical Rating Scale (NRS) for CAB LA + RPV LA Q4W Arm on Week 12- Thigh Injection Phase
Timepoint [11] 0 0
Week 12
Secondary outcome [12] 0 0
Number of Participants With Post-injection Pain Using Numerical Rating Scale (NRS)- Return to Gluteal Injection Phase
Timepoint [12] 0 0
Study Week 16
Secondary outcome [13] 0 0
HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Total Score at Indicated Time Points-Thigh Injection Phase
Timepoint [13] 0 0
Baseline (Day 1) and Week 16
Secondary outcome [14] 0 0
HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Total Score at Indicated Time Points for CAB LA + RPV LA Q8W Arm -Return to Gluteal Injection Phase
Timepoint [14] 0 0
Study Week 24
Secondary outcome [15] 0 0
HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Total Score at Indicated Time Points for CAB LA + RPV LA Q4W Arm -Return to Gluteal Injection Phase
Timepoint [15] 0 0
Study Week 20
Secondary outcome [16] 0 0
Change From Baseline in HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Individual Item Score at Indicated Time Points- Thigh Injection Phase
Timepoint [16] 0 0
Baseline (Day 1) and up to Week 16
Secondary outcome [17] 0 0
Change From Study Week 16 to Study Week 24 in HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Individual Item Score at Indicated Time Points for CAB LA + RPV LA Q8W Arm- Return to Gluteal Injection
Timepoint [17] 0 0
Study Week 16 and Study Week 24
Secondary outcome [18] 0 0
Change From Study Week 16 to Study Week 20 in HIV Treatment Satisfaction Questionnaire - Status Version (HIVTSQs) Individual Item Score at Indicated Time Points for CAB LA + RPV LA Q4W Arm- Return to Gluteal Injection Phase
Timepoint [18] 0 0
Study Week 16 and Study Week 20
Secondary outcome [19] 0 0
HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQc) Total Score at Indicated Time Points- Thigh Injection Phase
Timepoint [19] 0 0
Up to Week 16
Secondary outcome [20] 0 0
HIV Treatment Satisfaction Questionnaire - Change Version (HIVTSQc) Individual Item Score at Indicated Time Points- Thigh Injection Phase
Timepoint [20] 0 0
Up to Week 16
Secondary outcome [21] 0 0
Number of Participants With Their Treatment Preference as Assessed Using Preference Questionnaire for CAB LA + RPV LA Q8W Arm
Timepoint [21] 0 0
Up to Study Week 24
Secondary outcome [22] 0 0
Number of Participants With Their Treatment Preference as Assessed Using Preference Questionnaire for CAB LA + RPV LA Q4W Arm
Timepoint [22] 0 0
Up to Study Week 20

Eligibility
Key inclusion criteria
Sub-study specific

- Capable of giving sub-study specific informed consent.

- Eligible participants must have been on CAB LA + RPV LA regimen for a minimum of 152
weeks while on the ATLAS2-M study. Any disruptions in dosing during ATLAS2-M must be
discussed with the Medical Monitor for a final determination of eligibility into the
sub-study.

- Plasma HIV-1 RNA <50 copies/mL at Sub-Study Screening.

Inclusion criteria detailed for the ATLAS-2M main study apply to the sub-study:

- A female participant is eligible to participate if she is not pregnant (as confirmed
by a negative serum human chorionic gonadotropin [hCG] test) not lactating, and at
least one of the following conditions applies:

1. Non-reproductive potential defined as:

- Pre-menopausal females with one of the following:

i. Documented tubal ligation ii. Documented hysteroscopic tubal occlusion
procedure with follow-up confirmation of bilateral tubal occlusion iii.
Hysterectomy iv. Documented Bilateral Oophorectomy

- Postmenopausal defined as 12 months of spontaneous amenorrhea [in
questionable cases a blood sample with simultaneous follicle stimulating
hormone (FSH) and estradiol levels consistent with menopause. Females on
hormone replacement therapy (HRT) and whose menopausal status is in doubt
will be required to use one of the highly effective contraception methods if
they wish to continue their HRT during the study. Otherwise, they must
discontinue HRT to allow confirmation of post-menopausal status prior to
study enrollment.

2. Reproductive potential and agrees to follow one of the options listed in the
Modified List of Highly Effective Methods for Avoiding Pregnancy in Females of
Reproductive Potential (FRP) from 30 days prior to the first dose of study
medication, throughout the study, for at least 30 days after discontinuation of
all oral study medications, and for at least 52 weeks after discontinuation of
CAB LA and RPV LA.

- The investigator is responsible for ensuring that participants understand how to
properly use these methods of contraception.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
Sub-study specific

- Participants with more than 1 plasma HIV-1 RNA measurement >=50 copies/mL to <200
copies/mL (virologic blip) within 24 weeks prior to sub-study Screening visit.

- Any Suspected Virologic Failure (HIV-RNA greater than [>]200 copies/mL as defined in
during ATLAS-2M study.

- Participants planning to require oral bridging during participation in the ATLAS-2M
sub-study.

- The participant has a tattoo or any dermatological condition overlying the thigh
region which may interfere with interpretation of injection site reactions.

- Any condition which, in the opinion of the Investigator, may interfere with the
absorption, distribution, metabolism or excretion of the study drugs or render the
participant unable to receive study medication.

Exclusion criteria detailed for the ATLAS-2M main study apply to the sub-study:

- Women who are pregnant, breastfeeding or plan to become pregnant or breastfeed during
the study.

- Any evidence of a current Center for Disease Control and Prevention (CDC) Stage 3
disease, except cutaneous Kaposi's sarcoma not requiring systemic therapy, and Cluster
of Differentiation 4 positive (CD4+) counts <200 cells per microliter are not
exclusionary.

- Participants with moderate to severe hepatic impairment.

- Any pre-existing physical or mental condition (including substance use disorder)
which, in the opinion of the Investigator, may interfere with the participant's
ability to comply with the dosing schedule and/or protocol evaluations or which may
compromise the safety of the participant.

- Participants determined by the Investigator to have a high risk of seizures, including
participants with an unstable or poorly controlled seizure disorder. A participant
with a prior history of seizure may be considered for enrollment if the Investigator
believes the risk of seizure recurrence is low. All cases of prior seizure history
should be discussed with the Medical Monitor prior to enrollment.

- Participants who, in the investigator's judgment, pose a significant suicide risk.
Participant's recent history of suicidal behavior and/or suicidal ideation should be
considered when evaluating for suicide risk.

- Unstable liver disease (as defined by any of the following: presence of ascites,
encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, or
persistent jaundice or cirrhosis), known biliary abnormalities (with the exception of
Gilbert's syndrome or asymptomatic gallstones or otherwise stable chronic liver
disease per investigator assessment).

- History of liver cirrhosis with or without hepatitis viral co-infection.

- Ongoing or clinically relevant pancreatitis.

- Clinically significant cardiovascular disease, as defined by history/evidence of
congestive heart failure, symptomatic arrhythmia, angina/ischemia, coronary artery
bypass grafting (CABG) surgery or percutaneous transluminal coronary angioplasty
(PTCA) or any clinically significant cardiac disease.

- Ongoing malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or
resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial
neoplasia; other localized malignancies require agreement between the investigator and
the Study medical monitor for inclusion of the participant prior to randomization.

- Any condition which, in the opinion of the Investigator, may interfere with the
absorption, distribution, metabolism or excretion of the study drugs or render the
participant unable to receive study medication.

- History or presence of allergy or intolerance to the study drugs or their components
or drugs of their class. In addition, if heparin is used during PK sampling,
participants with a history of sensitivity to heparin or heparin-induced
thrombocytopenia must not be enrolled.

- Current or anticipated need for chronic anti-coagulation with the exception of the use
of low dose acetylsalicylic acid lesser than or equal to (<=)325 mg or hereditary
coagulation and platelet disorders such as hemophilia or Von Willebrand Disease.

- Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during
the Screening phase to verify a result.

- Any acute laboratory abnormality at Screening, which, in the opinion of the
investigator, would preclude the participant's participation in the study of an
investigational compound.

- Participant has estimated creatine clearance <50mL per minute per 1.73 square meter
via Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) Method.

- Alanine aminotransferase (ALT) >=3 × upper limit of normal (ULN) at Screening.

- Exposure to an experimental drug (with the exception of those in the ATLAS-2M study
including CAB, CAB LA, and RPV, RPV LA) or experimental vaccine within either 30 days,
5 half-lives of the test agent, or twice the duration of the biological effect of the
test agent, whichever is longer, prior to Day 1 of this study.

- Treatment with any of the following agents within 28 days of Screening:

i. radiation therapy; ii. cytotoxic chemotherapeutic agents; iii. tuberculosis therapy
with the exception of isoniazid (isonicotinylhydrazid [INH]); iv. anti-coagulation
agents; v. Immunomodulators that alter immune responses such as chronic systemic
corticosteroids, interleukins, or interferons

- Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening.

- Use of medications which are associated with Torsade de Pointes.

- Participants receiving any prohibited medication and who are unwilling or unable to
switch to an alternate medication.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
28/10/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
23/08/2022
Sample size
Target
Accrual to date
Final
118
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Georgia
Country [4] 0 0
United States of America
State/province [4] 0 0
Nebraska
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
Pennsylvania
Country [7] 0 0
United States of America
State/province [7] 0 0
Virginia
Country [8] 0 0
Argentina
State/province [8] 0 0
Buenos Aires
Country [9] 0 0
Argentina
State/province [9] 0 0
Santa Fe
Country [10] 0 0
Canada
State/province [10] 0 0
Ontario
Country [11] 0 0
Canada
State/province [11] 0 0
Saskatchewan
Country [12] 0 0
Germany
State/province [12] 0 0
Hessen
Country [13] 0 0
Germany
State/province [13] 0 0
Niedersachsen
Country [14] 0 0
Germany
State/province [14] 0 0
Berlin
Country [15] 0 0
Germany
State/province [15] 0 0
Hamburg
Country [16] 0 0
Italy
State/province [16] 0 0
Lombardia
Country [17] 0 0
Spain
State/province [17] 0 0
Badalona
Country [18] 0 0
Spain
State/province [18] 0 0
Barcelona
Country [19] 0 0
Spain
State/province [19] 0 0
Elche (Alicante)
Country [20] 0 0
Spain
State/province [20] 0 0
Madrid
Country [21] 0 0
Spain
State/province [21] 0 0
Malaga
Country [22] 0 0
Spain
State/province [22] 0 0
Santiago de Compostela
Country [23] 0 0
Spain
State/province [23] 0 0
Sevilla
Country [24] 0 0
Spain
State/province [24] 0 0
Valencia
Country [25] 0 0
Spain
State/province [25] 0 0
Vigo
Country [26] 0 0
Sweden
State/province [26] 0 0
Göteborg
Country [27] 0 0
Sweden
State/province [27] 0 0
Stockholm

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
ViiV Healthcare
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Janssen Research and Development
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
This sub-study will assess the pharmacokinetics (PK), safety, tolerability, virologic
efficacy and health outcomes of CAB (GSK1265744) and RPV long acting (LA) in HIV-infected
adult participants currently enrolled in the Antiretroviral Therapy as Long Acting
Suppression every 2 Months (ATLAS2M [A2M]) study (NCT03299049).
Trial website
https://clinicaltrials.gov/ct2/show/NCT05896761
Trial related presentations / publications
Public notes
This record is viewable in the ANZCTR as it had previously listed Australia and/or New Zealand as a recruitment site, however these sites have since been removed

Contacts
Principal investigator
Name 0 0
GSK Clinical Trials
Address 0 0
ViiV Healthcare
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT05896761